Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancer

As there were no significant outcome differences in DFS or OS between the studied schedules of AC and P with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.